Some previous studies on CER impacts with cancer drugs, such as trastuzumab/breast cancer [31], 5-FU/breast cancer [60], and temozolomide + radiotherapy/glioblastoma [11], showed increased drug effectivity; these studies commonly found changes in signaling pathways and ER stress with FASN inhibition. This evidence concerns the gene FASN and breast carcinoma.